In summary, we propose that FZD8 activates the canonical and non-canonical Wnt signaling pathway, plays an important role in the development of RCC, making FZD8 a potential RCC diagnosis biomarker and a putative promising drug target for human RCC therapy. This evidence concerns the gene FZD8 and renal cell carcinoma.